ArticleBMC cancer2023

Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.

Birgit S Geurts et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.